

**To:** [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@amsterdamumc.nl>; [redacted] <[redacted]@amsterdamumc.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>;  
**From:** [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@amsterdamumc.nl>  
**Sent:** Fri 11/20/2020 5:41:52 PM  
**Subject:** RE: Eerste opzet reactie naar GISAID  
**Received:** Fri 11/20/2020 5:41:53 PM

Dear [redacted]

I would like to really thank you for the valuable input and productive handling of this response.

Your support and input mean an awful lot to us.

Best, on behalf of [redacted]

Now it is time for a beer.

[redacted]

---

**From:** [redacted] <[redacted]@rivm.nl>  
**Sent:** vrijdag 20 november 2020 17:08  
**To:** [redacted] <[redacted]@amsterdamumc.nl>; [redacted] <[redacted]@amsterdamumc.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@amsterdamumc.nl>  
**Subject:** RE: Eerste opzet reactie naar GISAID

Hoi [redacted]

Prima reactie zo met de suggesties van de anderen daarbij.

Wat mij betreft akkoord om dit te versturen naar GISAID.

Prettig weekend,

[redacted]

---

**From:** [redacted] <[redacted]@amsterdamumc.nl>  
**Sent:** vrijdag 20 november 2020 16:11  
**To:** [redacted] <[redacted]@amsterdamumc.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@amsterdamumc.nl>  
**Subject:** Re: Eerste opzet reactie naar GISAID

Hi [redacted]

Much better version and excellent revisions by [redacted] I've made a few additional suggestions in [redacted] version. Have also included [redacted] just suggestion to mention AMC.

Best,

[redacted]

---

[redacted] | Amsterdam University Medical Centers  
 Academic Medical Center, [redacted] University of Amsterdam | Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands | phone [redacted]

---

**Van:** [redacted] <[redacted]@amsterdamumc.nl>  
**Verzonden:** vrijdag 20 november 2020 13:46  
**Aan:** [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@amsterdamumc.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@amsterdamumc.nl>  
**Onderwerp:** Re: Eerste opzet reactie naar GISAID

Hi [redacted] and all,

I've made some edits to the latest version of the letter. Please see attached.

As always, it's your call. I'm only trying to help.

All the best,

[redacted]

[redacted] | Department of Medical Microbiology | Amsterdam University Medical Center, University of Amsterdam

**From:** [redacted] <[redacted]@rivm.nl>

**Date:** Friday, 20 November 2020 at 11:37

**To:** "[redacted]@amsterdamumc.nl", [redacted]@amsterdamumc.nl, [redacted]@rivm.nl, [redacted]@rivm.nl, [redacted]@rivm.nl, [redacted]@rivm.nl, [redacted]@amsterdamumc.nl"

**Subject:** RE: Eerste opzet reactie naar GISAID

[redacted] Wederom veel dank voor jouw zeer waardevol inzichten suggesties.

En nieuwe opzet nav jouw suggesties (helpt zo lang)

Meer een open brief nu ipv een rebuttal \*

**From:** [redacted] <[redacted]@amsterdamumc.nl>

**Sent:** donderdag 19 november 2020 19:04

**To:** [redacted]@rivm.nl; [redacted]@amsterdamumc.nl; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@amsterdamumc.nl

**Subject:** Re: Eerste opzet reactie naar GISAID

Hi [redacted] and all,

I believe the response is too defensive, too (scientifically) explanatory and (much) too long. Personally I would respond more or less along the same lines and length as the response to the journal, e.g.:

- start by acknowledging the obvious importance of GISAID as an open science platform and the importance of trust and rules to keep this afloat, and emphasize that your institute contributes substantially to the success of GISAID, both directly by depositing human flu and Sars-cov-2 sequences as well as indirectly by facilitating sequence analyses by collaborating institutes (incl EMC) through sample collections within the Dutch public health network of GGDs.
- followed by part of the first paragraph of the previous response (We should emphasize that we have been acting in good faith, with no intended wrongdoing, in our research and the writing of our perspective. In this spirit we have openly communicated our findings in a national public health meeting attended by members of the Dutch 'mink consortium' in early October and more recently in a meeting attended by [redacted], the latter of which seems to have ignited the current predicament.) Add the bit about your failed attempts to preprint.
- then the ambiguity part of the previous response, ending with that you're looking forward to engage with GISAID to understand the exact rules of use and relieve the ambiguity for future reference.
- and then explain your solution for the current situation in order to not further delay sharing your important insights with the scientific community, particularly in relation to the conclusions of Koopman's recent Science paper, i.e. that observed mutations might be associated with mink-adaptation and have possible effects on the binding of neutralizing antibodies.

I think in this way this could be a more concise and stronger response but perhaps other feel differently.. It's your call!

Best,

5.1.2e

5.1.2e  
Academic Medical Center, 5.1.2e University of Amsterdam | Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands | phone 5.1.2e Amsterdam University Medical Centers

**Van:** 5.1.2e <5.1.2e@rivm.nl>

**Verzonden:** donderdag 19 november 2020 15:36

**Aan:** 5.1.2e 5.1.2e @amsterdamumc.nl>; 5.1.2e 5.1.2e @amsterdamumc.nl>; 5.1.2e 5.1.2e  
<5.1.2e @rivm.nl>; 5.1.2e <5.1.2e @rivm.nl>; 5.1.2e <5.1.2e @rivm.nl>;  
5.1.2e <5.1.2e @rivm.nl>; 5.1.2e ) <5.1.2e @amsterdamumc.nl>

**Onderwerp:** Eerste opzet reactie naar GISAID

Dear All,

5.1.2e

(voor juridisch advies),

5.1.2e

Please find attached a first set-up for the response to GISAID.

Input is welcome. It ended up being longer than intended as I tried to address the following:

- acted in good faith
- our manuscript is a perspective based on substitutions mentioned (but not discussed) in peer-reviewed published papers
- the gisaid data was used to provide context (prevalence) is is not the primary data source
- therefore acknowledgements seemed appropriate, instead of seeking collaboration
- DAA is ambitious, therefore for example not all authors registered as GISAID users, like pretty much any paper using GISAID (including 5.1.2e papers)

Looking forward to your input.

5.1.2e

**From:** 5.1.2e

**Sent:** Thursday, 19 November 2020 12:33

**To:** 5.1.2e | 5.1.2e@amsterdamumc.nl'

**Subject:** Fw: Demand to withhold publication by Virus Evolution of article authored by 5.1.2e et al



From: [REDACTED] <[REDACTED]@gisaid.org>  
 Sent: Monday, 16 November 2020 02:53  
 To: [REDACTED] [REDACTED]  
 Cc: Legal at GISAID  
 Subject: Demand to withhold publication by Virus Evolution of article authored by [REDACTED] et al

Please see the attached letter from the GISAID Secretariat.

Kindly note that this matter is urgent. We ask that you respond as soon as practicable, and no later than by 20<sup>th</sup> November 2020.

[REDACTED]  
 5.1.2e

*a Public-Private-Partnership with the Federal Republic of Germany*  
 Lipowskystraße 10 | 81373 Munich | Germany  
 District Court Munich Reg: VR204844  
[GISAID, from Vision to Reality](#)

This transmission is intended for the addressee(s) shown above. It contains information that is privileged, confidential or otherwise protected from disclosure. Any review, dissemination or use of this transmission or its contents by persons other than the intended addressee(s) is strictly prohibited. Should you have received this transmission in error, kindly notify us immediately and e-mail to us the original at the sender's address above, by replying to this message and including the test of the transmission received.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.  
[www.rivm.nl](http://www.rivm.nl) De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.  
[www.rivm.nl/en](http://www.rivm.nl/en) Committed to health and sustainability

---

VUmc disclaimer : [www.vumc.nl/disclaimer](http://www.vumc.nl/disclaimer)  
 AMC disclaimer : [www.amc.nl/disclaimer](http://www.amc.nl/disclaimer)

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.  
[www.rivm.nl](http://www.rivm.nl) De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.  
[www.rivm.nl/en](http://www.rivm.nl/en) Committed to health and sustainability